{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:44:39Z","timestamp":1740163479028,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T00:00:00Z","timestamp":1517961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T00:00:00Z","timestamp":1517961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CD8<jats:sup>+<\/jats:sup> T-cell expansions are the primary manifestation of T-cell large granular lymphocytic leukemia (T-LGLL), which is frequently accompanied by neutropenia and rheumatoid arthritis, and also occur as a secondary phenomenon in leukemia patients treated with dasatinib, notably in association with various drug-induced side-effects. However, the mechanisms that underlie the genesis and maintenance of expanded CD8<jats:sup>+<\/jats:sup> T-cell receptor (TCR)-V\u03b2<jats:sup>+<\/jats:sup> populations in these patient groups have yet to be fully defined. In this study, we performed a comprehensive phenotypic and clonotypic assessment of expanded (TCR-V\u03b2<jats:sup>+<\/jats:sup>) and residual (TCR-V\u03b2<jats:sup>\u2212<\/jats:sup>) CD8<jats:sup>+<\/jats:sup> T-cell populations in T-LGLL and dasatinib-treated chronic myelogenous leukemia (CML) patients. The dominant CD8<jats:sup>+<\/jats:sup> TCR-V\u03b2<jats:sup>+<\/jats:sup> expansions in T-LGLL patients were largely monoclonal and highly differentiated, whereas the dominant CD8<jats:sup>+<\/jats:sup> TCR-V\u03b2<jats:sup>+<\/jats:sup> expansions in dasatinib-treated CML patients were oligoclonal or polyclonal, and displayed a broad range of memory phenotypes. These contrasting features suggest divergent roles for antigenic drive in the immunopathogenesis of primary versus dasatinib-associated CD8<jats:sup>+<\/jats:sup> TCR-V\u03b2<jats:sup>+<\/jats:sup> expansions.<\/jats:p>","DOI":"10.1038\/s41598-017-18062-x","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T10:42:04Z","timestamp":1517481724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-V\u03b2+ expansions"],"prefix":"10.1038","volume":"8","author":[{"given":"Anna","family":"Lissina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"McLaren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"Ilander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3986-9892","authenticated-orcid":false,"given":"Emma I.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9280-5281","authenticated-orcid":false,"given":"Mathew","family":"Clement","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Herman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Ladell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sian","family":"Llewellyn-Lacey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly L.","family":"Miners","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Gostick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Joseph","family":"Melenhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. John","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Wooldridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"key":"18062_CR1","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1182\/blood-2013-05-506386","volume":"122","author":"MJ Clemente","year":"2013","unstructured":"Clemente, M. J. et al. Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. Blood 122, 4077\u20134085, https:\/\/doi.org\/10.1182\/blood-2013-05-506386 (2013).","journal-title":"Blood"},{"key":"18062_CR2","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1182\/blood-2011-02-338517","volume":"118","author":"MJ Clemente","year":"2011","unstructured":"Clemente, M. J. et al. Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood 118, 4384\u20134393, https:\/\/doi.org\/10.1182\/blood-2011-02-338517 (2011).","journal-title":"Blood"},{"key":"18062_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/sj.thj.6200212","volume":"4","author":"JJ Melenhorst","year":"2003","unstructured":"Melenhorst, J. J. et al. T-cell large granular lymphocyte leukemia is characterized by massive TCRBV-restricted clonal CD8 expansion and a generalized overexpression of the effector cell marker CD57. Hematol J 4, 18\u201325, https:\/\/doi.org\/10.1038\/sj.thj.6200212 (2003).","journal-title":"Hematol J"},{"key":"18062_CR4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s11899-007-0038-7","volume":"2","author":"L Sokol","year":"2007","unstructured":"Sokol, L. & Loughran, T. P. Jr. Large granular lymphocyte leukemia. Curr Hematol Malig Rep 2, 278\u2013282, https:\/\/doi.org\/10.1007\/s11899-007-0038-7 (2007).","journal-title":"Curr Hematol Malig Rep"},{"key":"18062_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/10245330600774793","volume":"11","author":"MW Wlodarski","year":"2006","unstructured":"Wlodarski, M. W., Schade, A. E. & Maciejewski, J. P. T-large granular lymphocyte leukemia: current molecular concepts. Hematology 11, 245\u2013256, https:\/\/doi.org\/10.1080\/10245330600774793 (2006).","journal-title":"Hematology"},{"key":"18062_CR6","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1182\/blood-2010-07-296962","volume":"117","author":"T Lamy","year":"2011","unstructured":"Lamy, T. & Loughran, T. P. Jr. How I treat LGL leukemia. Blood 117, 2764\u20132774, https:\/\/doi.org\/10.1182\/blood-2010-07-296962 (2011).","journal-title":"Blood"},{"key":"18062_CR7","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/sj.leu.2402645","volume":"16","author":"M Mohty","year":"2002","unstructured":"Mohty, M. et al. Features of large granular lymphocytes (LGL) expansion following allogeneic stem cell transplantation: a long-term analysis. Leukemia 16, 2129\u20132133, https:\/\/doi.org\/10.1038\/sj.leu.2402645 (2002).","journal-title":"Leukemia"},{"key":"18062_CR8","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood.V95.10.3219","volume":"95","author":"JH Liu","year":"2000","unstructured":"Liu, J. H. et al. Chronic neutropenia mediated by fas ligand. Blood 95, 3219\u20133222 (2000).","journal-title":"Blood"},{"key":"18062_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1046\/j.1365-2141.1997.d01-2113.x","volume":"97","author":"R Perzova","year":"1997","unstructured":"Perzova, R. & Loughran, T. P. Jr. Constitutive expression of Fas ligand in large granular lymphocyte leukaemia. Br J Haematol 97, 123\u2013126 (1997).","journal-title":"Br J Haematol"},{"key":"18062_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7326\/0003-4819-102-2-169","volume":"102","author":"TP Loughran Jr.","year":"1985","unstructured":"Loughran, T. P. Jr. et al. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med 102, 169\u2013175 (1985).","journal-title":"Ann Intern Med"},{"key":"18062_CR11","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/leu.2011.135","volume":"25","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman, A. et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 25, 1587\u20131597, https:\/\/doi.org\/10.1038\/leu.2011.135 (2011).","journal-title":"Leukemia"},{"key":"18062_CR12","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki, S. et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 23, 1398\u20131405, https:\/\/doi.org\/10.1038\/leu.2009.46 (2009).","journal-title":"Leukemia"},{"key":"18062_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4161\/cbt.27310","volume":"15","author":"ZY Qiu","year":"2014","unstructured":"Qiu, Z. Y., Xu, W. & Li, J. Y. Large granular lymphocytosis during dasatinib therapy. Cancer Biol Ther 15, 247\u2013255, https:\/\/doi.org\/10.4161\/cbt.27310 (2014).","journal-title":"Cancer Biol Ther"},{"key":"18062_CR14","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3109\/10428194.2010.550074","volume":"52","author":"JJ Powers","year":"2011","unstructured":"Powers, J. J. et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 52, 668\u2013679, https:\/\/doi.org\/10.3109\/10428194.2010.550074 (2011).","journal-title":"Leuk Lymphoma"},{"key":"18062_CR15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s12185-012-1132-8","volume":"96","author":"H Tanaka","year":"2012","unstructured":"Tanaka, H., Nakashima, S. & Usuda, M. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients. Int J Hematol 96, 308\u2013319, https:\/\/doi.org\/10.1007\/s12185-012-1132-8 (2012).","journal-title":"Int J Hematol"},{"key":"18062_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/leu.2016.174","volume":"31","author":"K Ishiyama","year":"2017","unstructured":"Ishiyama, K. et al. Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib. Leukemia 31, 203\u2013212, https:\/\/doi.org\/10.1038\/leu.2016.174 (2017).","journal-title":"Leukemia"},{"key":"18062_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3324\/haematol.13151","volume":"94","author":"DH Kim","year":"2009","unstructured":"Kim, D. H. et al. Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica 94, 135\u2013139, https:\/\/doi.org\/10.3324\/haematol.13151 (2009).","journal-title":"Haematologica"},{"key":"18062_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1046\/j.1365-2141.2001.02509.x","volume":"112","author":"JJ Melenhorst","year":"2001","unstructured":"Melenhorst, J. J., Sorbara, L., Kirby, M., Hensel, N. F. & Barrett, A. J. Large granular lymphocyte leukaemia is characterized by a clonal T-cell receptor rearrangement in both memory and effector CD8(+) lymphocyte populations. Br J Haematol 112, 189\u2013194 (2001).","journal-title":"Br J Haematol"},{"key":"18062_CR19","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.4049\/jimmunol.172.3.1960","volume":"172","author":"CL O\u2019Keefe","year":"2004","unstructured":"O\u2019Keefe, C. L. et al. Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses. J Immunol 172, 1960\u20131969 (2004).","journal-title":"J Immunol"},{"key":"18062_CR20","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3324\/haematol.2009.018481","volume":"95","author":"B Bareau","year":"2010","unstructured":"Bareau, B. et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica 95, 1534\u20131541, https:\/\/doi.org\/10.3324\/haematol.2009.018481 (2010).","journal-title":"Haematologica"},{"key":"18062_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1172\/JCI9940","volume":"107","author":"PK Epling-Burnette","year":"2001","unstructured":"Epling-Burnette, P. K. et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107, 351\u2013362, https:\/\/doi.org\/10.1172\/JCI9940 (2001).","journal-title":"J Clin Invest"},{"key":"18062_CR22","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2005-08-3076","volume":"107","author":"AE Schade","year":"2006","unstructured":"Schade, A. E., Powers, J. J., Wlodarski, M. W. & Maciejewski, J. P. Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. Blood 107, 4834\u20134840, https:\/\/doi.org\/10.1182\/blood-2005-08-3076 (2006).","journal-title":"Blood"},{"key":"18062_CR23","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/onc.2012.347","volume":"32","author":"W Vainchenker","year":"2013","unstructured":"Vainchenker, W. & Constantinescu, S. N. JAK\/STAT signaling in hematological malignancies. Oncogene 32, 2601\u20132613, https:\/\/doi.org\/10.1038\/onc.2012.347 (2013).","journal-title":"Oncogene"},{"key":"18062_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.65","volume":"3","author":"EI Andersson","year":"2013","unstructured":"Andersson, E. I. et al. Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. Blood Cancer J 3, e168, https:\/\/doi.org\/10.1038\/bcj.2013.65 (2013).","journal-title":"Blood Cancer J"},{"key":"18062_CR25","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","volume":"120","author":"A Jerez","year":"2012","unstructured":"Jerez, A. et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 120, 3048\u20133057, https:\/\/doi.org\/10.1182\/blood-2012-06-435297 (2012).","journal-title":"Blood"},{"key":"18062_CR26","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","volume":"366","author":"HL Koskela","year":"2012","unstructured":"Koskela, H. L. et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 366, 1905\u20131913, https:\/\/doi.org\/10.1056\/NEJMoa1114885 (2012).","journal-title":"N Engl J Med"},{"key":"18062_CR27","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/leu.2015.263","volume":"30","author":"E Andersson","year":"2016","unstructured":"Andersson, E. et al. Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. Leukemia 30, 1204\u20131208, https:\/\/doi.org\/10.1038\/leu.2015.263 (2016).","journal-title":"Leukemia"},{"key":"18062_CR28","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1182\/blood-2012-12-474577","volume":"121","author":"HL Rajala","year":"2013","unstructured":"Rajala, H. L. et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 121, 4541\u20134550, https:\/\/doi.org\/10.1182\/blood-2012-12-474577 (2013).","journal-title":"Blood"},{"key":"18062_CR29","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/leu.2012.348","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki, S. et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 27, 914\u2013924, https:\/\/doi.org\/10.1038\/leu.2012.348 (2013).","journal-title":"Leukemia"},{"key":"18062_CR30","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1182\/blood-2002-07-2103","volume":"101","author":"JM Brenchley","year":"2003","unstructured":"Brenchley, J. M. et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101, 2711\u20132720, https:\/\/doi.org\/10.1182\/blood-2002-07-2103 (2003).","journal-title":"Blood"},{"key":"18062_CR31","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.4049\/jimmunol.0900182","volume":"183","author":"C Petrovas","year":"2009","unstructured":"Petrovas, C. et al. Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection. J Immunol 183, 1120\u20131132, https:\/\/doi.org\/10.4049\/jimmunol.0900182 (2009).","journal-title":"J Immunol"},{"key":"18062_CR32","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/nri1226","volume":"3","author":"K Shuai","year":"2003","unstructured":"Shuai, K. & Liu, B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3, 900\u2013911, https:\/\/doi.org\/10.1038\/nri1226 (2003).","journal-title":"Nat Rev Immunol"},{"key":"18062_CR33","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9, 798\u2013809, https:\/\/doi.org\/10.1038\/nrc2734 (2009).","journal-title":"Nat Rev Cancer"},{"key":"18062_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc1275","volume":"4","author":"H Yu","year":"2004","unstructured":"Yu, H. & Jove, R. The STATs of cancer \u2013 new molecular targets come of age. Nat Rev Cancer 4, 97\u2013105, https:\/\/doi.org\/10.1038\/nrc1275 (2004).","journal-title":"Nat Rev Cancer"},{"key":"18062_CR35","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/leu.2012.350","volume":"27","author":"A Fasan","year":"2013","unstructured":"Fasan, A. et al. STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia 27, 1598\u20131600, https:\/\/doi.org\/10.1038\/leu.2012.350 (2013).","journal-title":"Leukemia"},{"key":"18062_CR36","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.4161\/cc.5.22.3449","volume":"5","author":"AE Schade","year":"2006","unstructured":"Schade, A. E., Wlodarski, M. W. & Maciejewski, J. P. Pathophysiology defined by altered signal transduction pathways: the role of JAK-STAT and PI3K signaling in leukemic large granular lymphocytes. Cell Cycle 5, 2571\u20132574, https:\/\/doi.org\/10.4161\/cc.5.22.3449 (2006).","journal-title":"Cell Cycle"},{"key":"18062_CR37","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S0145-2126(01)00010-8","volume":"25","author":"JJ Melenhorst","year":"2001","unstructured":"Melenhorst, J. J., Brummendorf, T. H., Kirby, M., Lansdorp, P. M. & Barrett, A. J. CD8+ T cells in large granular lymphocyte leukemia are not defective in activation- and replication-related apoptosis. Leuk Res 25, 699\u2013708 (2001).","journal-title":"Leuk Res"},{"key":"18062_CR38","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.leukres.2013.10.002","volume":"37","author":"T Ren","year":"2013","unstructured":"Ren, T. et al. Developing an in vitro model of T cell type of large granular lymphocyte leukemia. Leuk Res 37, 1737\u20131743, https:\/\/doi.org\/10.1016\/j.leukres.2013.10.002 (2013).","journal-title":"Leuk Res"},{"key":"18062_CR39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood.V89.1.201","volume":"89","author":"R Zambello","year":"1997","unstructured":"Zambello, R. et al. Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood 89, 201\u2013211 (1997).","journal-title":"Blood"},{"key":"18062_CR40","doi-asserted-by":"publisher","first-page":"16308","DOI":"10.1073\/pnas.0806447105","volume":"105","author":"R Zhang","year":"2008","unstructured":"Zhang, R. et al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci USA 105, 16308\u201316313, https:\/\/doi.org\/10.1073\/pnas.0806447105 (2008).","journal-title":"Proc Natl Acad Sci USA"},{"key":"18062_CR41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/icb.2010.139","volume":"89","author":"JJ Miles","year":"2011","unstructured":"Miles, J. J., Douek, D. C. & Price, D. A. Bias in the alphabeta T-cell repertoire: implications for disease pathogenesis and vaccination. Immunol Cell Biol 89, 375\u2013387, https:\/\/doi.org\/10.1038\/icb.2010.139 (2011).","journal-title":"Immunol Cell Biol"},{"key":"18062_CR42","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah, N. P. et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26, 3204\u20133212, https:\/\/doi.org\/10.1200\/JCO.2007.14.9260 (2008).","journal-title":"J Clin Oncol"},{"key":"18062_CR43","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","volume":"14","author":"R Weichsel","year":"2008","unstructured":"Weichsel, R. et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 14, 2484\u20132491, https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4393 (2008).","journal-title":"Clin Cancer Res"},{"key":"18062_CR44","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/ajh.20981","volume":"82","author":"D Rossi","year":"2007","unstructured":"Rossi, D. et al. Transient monoclonal expansion of CD8+ \/CD57+ T-cell large granular lymphocytes after primary cytomegalovirus infection. Am J Hematol 82, 1103\u20131105, https:\/\/doi.org\/10.1002\/ajh.20981 (2007).","journal-title":"Am J Hematol"},{"key":"18062_CR45","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1172\/JCI114847","volume":"86","author":"JG Strickler","year":"1990","unstructured":"Strickler, J. G. et al. Oligoclonal T cell receptor gene rearrangements in blood lymphocytes of patients with acute Epstein-Barr virus-induced infectious mononucleosis. J Clin Invest 86, 1358\u20131363, https:\/\/doi.org\/10.1172\/JCI114847 (1990).","journal-title":"J Clin Invest"},{"key":"18062_CR46","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","volume":"116","author":"A Kreutzman","year":"2010","unstructured":"Kreutzman, A. et al. Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 116, 772\u2013782, https:\/\/doi.org\/10.1182\/blood-2009-12-256800 (2010).","journal-title":"Blood"},{"key":"18062_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3324\/haematol.2014.113142","volume":"100","author":"HL Rajala","year":"2015","unstructured":"Rajala, H. L. et al. The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. Haematologica 100, 91\u201399, https:\/\/doi.org\/10.3324\/haematol.2014.113142 (2015).","journal-title":"Haematologica"},{"key":"18062_CR48","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1126\/science.274.5284.94","volume":"274","author":"JD Altman","year":"1996","unstructured":"Altman, J. D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94\u201396 (1996).","journal-title":"Science"},{"key":"18062_CR49","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1084\/jem.20051357","volume":"202","author":"DA Price","year":"2005","unstructured":"Price, D. A. et al. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med 202, 1349\u20131361, https:\/\/doi.org\/10.1084\/jem.20051357 (2005).","journal-title":"J Exp Med"},{"key":"18062_CR50","doi-asserted-by":"publisher","unstructured":"Quigley, M. F., Almeida, J. R., Price, D. A. & Douek, D. C. Unbiased molecular analysis of T cell receptor expression using template-switch anchored RT-PCR. Curr Protoc Immunol Chapter 10, Unit10:33, https:\/\/doi.org\/10.1002\/0471142735.im1033s94 (2011).","DOI":"10.1002\/0471142735.im1033s94"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18062-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:15:11Z","timestamp":1671588911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-18062-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["18062"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-18062-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2018,2,7]]},"assertion":[{"value":"19 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.M. has received honoraria and research funding from Novartis, Pfizer, and Bristol-Myers Squibb, and research funding from Ariad (unrelated to this project). The other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2534"}}